Omeros (OMER) Competitors $10.31 +0.07 (+0.68%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OMER vs. PCRX, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Pacira BioSciences Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment. Does the MarketBeat Community favor OMER or PCRX? Pacira BioSciences received 81 more outperform votes than Omeros when rated by MarketBeat users. Likewise, 71.59% of users gave Pacira BioSciences an outperform vote while only 71.03% of users gave Omeros an outperform vote. CompanyUnderperformOutperformOmerosOutperform Votes74371.03% Underperform Votes30328.97% Pacira BioSciencesOutperform Votes82471.59% Underperform Votes32728.41% Do institutionals and insiders hold more shares of OMER or PCRX? 48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 12.3% of Omeros shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is OMER or PCRX more profitable? Omeros has a net margin of 0.00% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -49.92% Pacira BioSciences -13.07%13.42%7.19% Which has more volatility & risk, OMER or PCRX? Omeros has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Does the media refer more to OMER or PCRX? In the previous week, Omeros and Omeros both had 12 articles in the media. Omeros' average media sentiment score of 0.88 beat Pacira BioSciences' score of 0.27 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 6 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, OMER or PCRX? Pacira BioSciences has higher revenue and earnings than Omeros. Pacira BioSciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$117.81M-$2.31-4.46Pacira BioSciences$694.96M1.26$41.96M-$2.03-9.35 Do analysts rate OMER or PCRX? Omeros presently has a consensus price target of $9.00, indicating a potential downside of 12.71%. Pacira BioSciences has a consensus price target of $23.50, indicating a potential upside of 23.81%. Given Pacira BioSciences' higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Omeros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Pacira BioSciences 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryPacira BioSciences beats Omeros on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$597.46M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-4.4610.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book-25.785.104.794.78Net Income-$117.81M$151.51M$120.07M$225.60M7 Day Performance35.12%-2.14%-1.90%-1.24%1 Month Performance33.38%-3.13%11.43%3.06%1 Year Performance224.21%11.51%30.59%16.50% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros2.712 of 5 stars$10.31+0.7%$9.00-12.7%+244.8%$597.47MN/A-4.46198Analyst ForecastNews CoverageHigh Trading VolumePCRXPacira BioSciences3.7422 of 5 stars$20.13+1.4%$23.50+16.7%-41.1%$929.40M$674.98M-9.78720Gap DownNKTRNektar Therapeutics4.3623 of 5 stars$1.03+2.0%$4.10+298.1%+95.6%$189.99M$93.14M-1.20220News CoverageGap UpASMBAssembly Biosciences3.8163 of 5 stars$15.50+0.8%$35.00+125.8%+64.6%$98.52M$28.33M0.00100News CoverageCPIXCumberland Pharmaceuticals0.3277 of 5 stars$2.17-8.8%N/A+30.5%$30.47M$36.79M-2.8380Analyst ForecastNews CoverageGap DownLLYEli Lilly and Company4.9956 of 5 stars$779.34-1.2%$1,002.22+28.6%+34.6%$739.84B$40.86B85.4843,000Gap UpJNJJohnson & Johnson4.8952 of 5 stars$145.04-1.1%$174.73+20.5%-5.7%$349.20B$87.70B21.22131,900ABBVAbbVie4.9342 of 5 stars$172.71-0.4%$203.65+17.9%+15.7%$305.20B$55.53B60.2350,000Analyst ForecastInsider TradeMRKMerck & Co., Inc.4.9889 of 5 stars$100.98-0.2%$129.20+27.9%-6.9%$255.44B$60.12B21.3172,000Analyst DowngradePFEPfizer4.9837 of 5 stars$25.48-0.4%$32.15+26.2%-4.6%$144.39B$58.50B34.7688,000Analyst ForecastOptions VolumeAnalyst RevisionBMYBristol-Myers Squibb4.7872 of 5 stars$56.20+0.8%$55.64-1.0%+12.5%$113.98B$47.44B-15.5434,100 Related Companies and Tools Related Companies PCRX Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMER) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
